Which of the following is NOT a mechanism of action (MOA) for Metformin?

Metformin is a medication that primarily acts to improve insulin sensitivity and lower blood glucose levels in individuals with type 2 diabetes. One of its main mechanisms of action is to enhance insulin sensitivity in peripheral tissues, which facilitates better glucose uptake by the muscles and fat cells. This action contributes to the reduction of blood glucose levels.

Additionally, Metformin reduces the amount of glucose absorbed from the gastrointestinal tract, helping to limit the rise in blood glucose levels after meals. Moreover, it also decreases hepatic glucose production, particularly by inhibiting gluconeogenesis in the liver. This is crucial in managing hyperglycemia in diabetic patients.

The choice that is not a mechanism of action for Metformin is increasing hepatic glucose production. Instead, Metformin's role is to decrease it. This underscores the importance of understanding the exact physiological effects and mechanisms by which Metformin operates in the context of glucose metabolism and diabetes management.